Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMP · IEX Real-Time Price · USD
2.520
-0.060 (-2.33%)
Apr 12, 2024, 4:30 PM EDT - Market closed
-2.33%
Market Cap 102.11M
Revenue (ttm) 1.34M
Net Income (ttm) 5.53M
Shares Out 40.52M
EPS (ttm) 0.14
PE Ratio 18.00
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,501
Open 2.590
Previous Close 2.580
Day's Range 2.500 - 2.640
52-Week Range 1.670 - 5.250
Beta 1.82
Analysts Hold
Price Target 2.00 (-20.63%)
Earnings Date May 9, 2024

About ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 13
Stock Exchange NASDAQ
Ticker Symbol ORMP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ORMP stock is "Hold" and the 12-month stock price forecast is $2.0.

Price Target
$2.0
(-20.63% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Oramed Letter to Shareholders

Initiating Phase 3 oral insulin trial in the United States under a new protocol  JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing  NEW YORK , ...

7 weeks ago - PRNewsWire

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously ...

7 months ago - PRNewsWire

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally

JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to...

9 months ago - PRNewsWire

Oramed to Present at the 83rd American Diabetes Association Conference

NEW YORK , June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at...

10 months ago - PRNewsWire

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

NEW YORK , May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-per...

11 months ago - PRNewsWire

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK , May 15, 2023 /PRNewswire/ -- Oramed Pharmaceu...

11 months ago - PRNewsWire

Oramed Pharmaceuticals Issues Shareholder Update

NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from...

1 year ago - PRNewsWire

Oramed's oral insulin pill fails; stock is down 72%

Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or second...

1 year ago - Market Watch

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced ...

1 year ago - PRNewsWire

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...

1 year ago - PRNewsWire

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliv...

1 year ago - PRNewsWire

MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

- MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty ...

1 year ago - PRNewsWire

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Medicox to Distribute Oramed's Oral Insulin in South Korea, if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed to Receive up to 15% Royalties on Gross Sales Large Marke...

1 year ago - PRNewsWire

Oramed Reports Third Quarter 2022 Financial Results

NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the de...

1 year ago - PRNewsWire

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it wi...

1 year ago - PRNewsWire

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept ...

1 year ago - PRNewsWire

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatmen...

1 year ago - PRNewsWire

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliv...

1 year ago - PRNewsWire

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

-  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol -  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK , July 26, 20...

1 year ago - PRNewsWire

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

NEW YORK , July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliv...

1 year ago - PRNewsWire

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

NEW YORK , June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, tod...

2 years ago - PRNewsWire

Oramed to Present at H.C. Wainwright Global Investment Conference

NEW YORK , May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliver...

2 years ago - PRNewsWire

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected i...

2 years ago - PRNewsWire

Oramed Appoints Yadin Rozov to its Board of Directors

NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today annou...

2 years ago - PRNewsWire

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...

2 years ago - PRNewsWire